Therefore, edaravone has the potential to activate the Nrf2/ARE signaling pathway by regulating Nrf2 at the transcriptional and translational levels, as well as at the translocation step [44], under the neurotoxic condition of TDP-43 proteinopathy. Here, NFE2L2 is linked to proteostasis deficiencies.